According to the report, Merck & Co IncThere may be a risk of underestimation in the way COVID-19 takes Molnupiravir orally to destroy the SARS-CoV-2 virus.

It is reported that Molnupiravir embeds itself into the genetic material of SARS-CoV-2 virus, resulting in a large number of mutations in the process of virus replication, eventually killing the virus. However, some laboratory tests have shown that the drug has the ability to enter the genetic material of mammalian cells. Because the drug can cause mutations, it could theoretically cause birth defects or cancer.

Nathaniel Landau, a professor of microbiology at the Grossman School of Medicine at New York University, said: "given the possibility that the drug may be integrated into cellular DNA, it is important to prove that there is no cancer in animal and human experiments."

Merck & Co Inc said animal tests conducted by the company showed that these concerns were unfounded.

Last week, Merck & Co Inc and his partner Ridgeback Biotherapeutics LP issued a statement saying that based on preliminary analysis of later-stage clinical trials, the company's experimental novel coronavirus drug could reduce the risk of severe illness and death by 50 per cent. This result may eventually mean that many patients infected with the virus can get simple and convenient treatment at home. The company's share price immediately posted its biggest rise in 12 years.

Rob Davis, CEO of Merck & Co Inc, said that the two companies now plan to apply to FDA for emergency use authorization as soon as possible. If the drug enters the market, it will be an important milestone in the epidemic.